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PRM253
An EPidEMiologic ModEling APPlicAtion to PhARMAcoEconoMics foR 
iMPRovEd hEAlth cARE PlAnning
Cid Ruzafa J., Cox A., Merinopoulou E., Baggaley R., Leighton P., Desai K.
Evidera, London, UK
Epidemiologic and pharmacoeconomic models differ in terms of populations con-
sidered, mathematical techniques used, and questions addressed. A typical pharma-
coeconomic model assesses chronic or acute conditions, uses Markov techniques, 
and considers a closed patient group receiving a defined therapy to assess incre-
mental costs needed to achieve gains in quality adjusted life years. A typical epide-
miologic model assesses vaccination or public health interventions for infectious 
disease using differential equations and considers open populations representing 
communities to estimate prevalence or numbers of disease cases averted. The man-
ner of conducting sensitivity analyses also differs. In oncology, in which multiple 
lines of treatment are available, the epidemiologic approach has application to esti-
mate the patient point prevalence or the number of patients who can start on a line 
of therapy over a certain time period, when this cannot be determined from clinical 
trials or registers (which usually focus on single lines of therapy or limited types of 
patients that are not representative of the overall patient population). The approach 
consists of conceptualizing an open population that incorporates incidence of the 
condition and the transition of patients through various lines of treatment until 
death, and uses systems of difference/differential equations. Parameterization is 
challenging if there are several prognostic factors to describe the patient population, 
multiple or complex treatment pathways, and a wide range of variability. Parameters 
are obtained from the published literature, analyses of database information, and/
or surveys to experts in the field. Steady state solutions of the model equations 
estimate point and period prevalence. This approach is applicable to gastrointesti-
nal stromal tumours and multiple myeloma. Resulting estimates are important for 
budget impact analysis and health care services planning by reducing uncertainty 
associated with identifying the patient numbers eligible for a given treatment. 
Epidemiologic modelling permits a framework to estimate disease prevalence that 
is little used in pharmacoeconomics.
PRM254
non-intERvEntionAl REsEARch EthicAl REquiREMEnts in EnglAnd And 
fRAncE: shAREd ExPERiEncE fRoM A BinAtionAl REsEARch PRojEct
Guillemot J., Boval M.C., Gauthier A.
Amaris, London, UK
BAckground: Ethical review for non-interventional research is progressively becom-
ing part of research standards. This evolution ensures that participants in research 
are respectfully considered. In practice, information on ethical requirements for non-
interventional research seems insufficient. Increasing and legitimate expectations 
from peer-reviewed journals regarding reviews by ethics committees sometimes 
challenge researchers. In this presentation, we share our experience of investigating 
ethical requirements for conducting a questionnaire-based research on physicians in 
France and England. Methods: This investigation consisted of a documentary analy-
sis, including official guidance documents on ethical requirements, communications 
with institutions and publications reviews. Documents were identified using an ad 
hoc search on official websites. Publications were identified on PubMed. Findings: 
In England, the service of the National Research Ethics Service (NRES) serves as the 
ethics reviewer. It offers an informal preliminary review of the study protocol and esti-
mates ethical risks associated with non-interventional research projects. Depending 
of the target population, the methods and the risk level associated with the research 
project, the NRES states whether a formal ethics application is necessary or not. In 
case of low risk projects the NRES supplies an email which can be used as a justifica-
tion for peer-reviewed journals. In France, structures to support ethical reviews for 
non-interventional research are the result of an on-going reform. Comités de Protection 
de la Personne, or CPPs, fulfil the role of ethics reviewers although they were initially 
designed to collaborate for hospital-based research. Gaining ethical review in France 
was more complex due to the infrequent character of such request from the indus-
try. conclusion: This experience showed the increasing role of ethical require-
ments in non-interventional research. It is a domain in constant movement which 
calls for innovative approaches to compile and disseminate information regarding 
ethical requirements for non-interventional research across Europe and the world, 
especially regarding cross-national research projects.
PRM255
REAl WoRld studiEs, chAllEngEs, nEEds And tREnds fRoM thE 
industRy
Batrouni M., Comet D., Meunier J.P.
Axonal, Paris, France
oBjectives: To understand key challenges, needs and trends for conducting real 
world studies (RWS). Methods: An online survey conducted in September 2013 
within key players in the pharmaceutical and medical device industry in EU and US. 
456 persons have been solicited through emails and phone calls, 107 have responded 
to the questionnaire. Respondents were mostly occupying senior positions in medi-
cal affairs, health economics and outcome research. results: 27% RWS conducted 
are requested by Health Authorities, 73% on the industry initiative. 75% of those 
studies are subcontracted to a CRO. The main criteria of choice are the experience 
in RWS, particularly in the regulation process, the capacity to deliver on time and a 
flexible and adaptable structure. The RWS activity is expected to increase by 25 % in 
the next two years. Most of those studies have safety and effectiveness objectives 
and to a lesser extent drug utilization and health economics and the most common 
therapeutic areas are: oncology, cardiovascular and metabolic disorders. In addition, 
pharmaceutical companies are conducting more and more epidemiological studies 
to prepare dossiers for market access (disease understanding, unmet needs, popula-
tion targeting). conclusion: The pharmaceutical market is becoming global and 
is expanding into new countries and therapeutic areas. The result is an increase 
in the need for RWS where the regulatory agencies are asking for additional data 
PRM250
PAthWAys of iMPlEMEntAtion of Multi-cRitERiA dEcision AnAlysis 
into oRPhAn dRug APPRovAl PRocEduRE foR dRug suPPly PRogRAMs in 
RussiAn fEdERAtion
Serpik V.G.1, Yagudina R.I.2
1National Research Institute of Public Health, Moscow, Russia, 2First Moscow State Medical 
University named after I. M. Sechenov, Moscow, Russia
BAckground: While the orphan drug supply program is in progress, development 
of decision-making rules for approving orphan drug for supply program of Russian 
Federation becomes very actual. Real world data provides evidence, that routine 
approaches for approving such kind of drugs, e.i. pharmacoeconomic conclusions, 
are not applicable. Than the need in more appropriate approaches is existed. 
Multi-criteria decision analysis is one such approaches (MCDA). oBjective: To 
evaluate prospective of implementation of MCDA in health care system of Russian 
Federation and to develop road map of MCDA in Russia. Methods: Literature 
review, cluster analysis, interviewing experts. results: The first step (qualitive) 
to implement MCDA is to test various MCDA methods to find out optimal one for 
Russian Federation: it is expected to select the most relevant criteria from the wide 
range of them. First of all, MCDA is considered to be the instrument to improve the 
quality of discussion and its transparency, to underline different point of view and 
unmet needs. On the second stage it may be possible to use quantity MCDA assess-
ment as a rule to approve orphan drugs for drug supply programs. Local recom-
mendations for MCDA in Russian Federation has been published. conclusion: 
Implementation of MCDA as assisting instrument for orphan drug approving for 
drug supply programs is likely to be a valuable approach, that may improve the 
quality, transparency of decision-making process and to provide social equity for 
accepting decisions.
PRM251
PRoPEnsity scoRE MAtching And suBclAssificAtion With Multi-lEvEl 
tREAtMEnts
Kadziola Z.1, Yang S.2, Imbens G.W.3, Cui Z.4, Faries D.E.4
1Eli Lilly Regional Operations GmbH, Vienna, Austria, 2Harvard School of Public Health, Boston, 
MA, USA, 3Graduate School of Business, Stanford University, and NBER, Stanford, CA, USA,, 4Eli 
Lilly and Company, Indianapolis, IN, USA
There is extensive literature on methods, such as propensity scoring, for esti-
mating the causal effects for two treatments using real world data. Much less 
work has been done for the more general setting with three or more treatments. 
Whereas the literature has suggested that these propensity-based methods do 
not naturally extend to the multi-level treatment case, we show, using the con-
cept of weak unconfoundedness, that adjusting for or matching on a scalar func-
tion of the covariates removes biases associated with observed covariates. We 
focused on subclassification and matching approaches as these have found to 
be effective for two treatments and are among the most popular methods in 
that setting. We apply the proposed methods to an analysis of the effectiveness 
of treatments for fibromyalgia from a prospective observational study. We also 
carried out a simulation study to assess the performance of those new methods 
relative to such approaches like: pairwise propensity score matching; matching 
on the Mahalanobis distance of all covariates; matching on the set of propensity 
scores (with the number of scores equal to the number of distinct treatment lev-
els minus one (Rassen, 2013)); weighting on the inverse of the binary treatment 
propensity scores (McCaffrey, 2013). The simulations suggest that the proposed 
methods are simple and viable options for comparing the effectiveness of three 
or more treatments. RASSEN et al.: Matching by propensity score in cohort studies 
with three treatment groups. Epidemiology 24, 401–9. MCCAFFREY et al.: A tutorial 
on propensity score estimation for multiple treatments using generalized boosted 
models. Stat. Med. 32,3388–414.
PRM252
gEtting to REiMBuRsEMEnt fAstER: coMBining RAndoMisEd, 
PRAgMAtic, And oBsERvAtionAl clinicAl tRiAl dAtA
Alsop J.
Numerus Ltd, Wokingham, UK
Reimbursement authorities often require pharmaceutical companies to provide 
them with more than just placebo-controlled data from RCTs. Instead, they typi-
cally seek data from a wider “real-world” setting, where the focus is on generating 
evidence of comparative effectiveness. The natural temptation for many phar-
maceutical companies is to provide this evidence from separate, post-market 
approval studies. However, this approach can be expensive and undoubtedly leads 
to delays in reimbursement. We propose that both the additional costs of evidence 
gathering and the delays between regulatory and reimbursement approvals could 
be reduced by combining the main design elements of randomised, pragmatic, 
and prospective observational studies into a single, integrated Phase 3/4 study. 
This single study approach would typically begin with a standard RCT phase 
where, for example, an initial cohort of patients would be randomised to receive 
either the investigational therapy or placebo. Either in parallel with or follow-
ing this phase, a second patient cohort would be randomised under pragmatic 
clinical trial conditions with the aim of comparing the investigational therapy 
with placebo and a limited number of active comparator treatments. Lastly, a 
third (observational) cohort would be enrolled and allocated to a wider range 
of therapies, as per clinical practice. Data from the RCT cohort would be used 
to obtain limited regulatory approval. Following this, data from the pragmatic 
cohort, once available, would then be formally combined using standard statistical 
techniques with data from the RCT cohort in order to obtain a wider regulatory 
approval and possibly some form of conditional reimbursement. The pragmatic 
and observational cohorts would then provide the comparative effectiveness 
data to allow for reimbursement across different patient groups. We outline the 
strengths and weaknesses of this approach, and discuss its operational consid-
erations.
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ber of exacerbations during the 6 month follow-up following initial exacerbation. 
We also compared health care utilization between both groups. results: Among 
115,489 infants (mean age: 13.9 months; 62.9% boys), 4,477 infants of the MTL-4 
group were matched with 13,386 infants of the ICS group. In multivariate analysis, 
the risk of a new exacerbation was lower in infants of MTL-4 group compared to 
infants in ICS group (HR= 0.91, IC95% [0.87; 0.95]). The total number of exacerbations 
did not differ between the 2 groups during the 6-month follow-up (p= 0,8617), nei-
ther the cost of asthma management (344€ for MTL-4 group vs. 308€ for ICS group, 
p= 0.1410). conclusions: MTL-4 and ICS appear to be comparable therapeutic 
strategies, with similar effects on exacerbation and equivalent costs. The SNIIR-AM 
allows conducting comparative effectiveness research.
PRs3
clinicAl tRiAl-BAsEd cost-EffEctivEnEss AnAlysis of indAcAtERol 
(onBREZ® 150 Mcg) vERsus tiotRoPiuM (sPiRivA®) in thE tREAtMEnt of 
chRonic oBstRuctivE PulMonARy disEAsE (coPd) in tuRKEy
Saylan M., Beykoz V., Keskinaslan A.
Novartis Pharma, Istanbul, Turkey
oBjectives: COPD is a disease that is characterized by chronic and progressive 
restriction of the airflow. The cost of COPD medications can be reduced signifi-
cantly by implementing a treatment algorithm that is consistent with the GOLD 
guidelines. Indacaterol and tiotrpium administered by inhalation are indicated for 
maintenance treatment of COPD in Turkey. We aimed to compare, from the perspec-
tive of the Turkish social security institution, the cost-effectiveness of indacaterol 
150 mcg once daily and long-acting tiotropium 18 mcg once daily at months 3 and 
6 in patients with moderate to severe COPD aged 30 years and above. Methods: 
From payer perspective, a cost-effectiveness analysis based on two separate clinical 
trials (INTENSITY-once daily indacaterol and tiotropium vs. placebo and INHANCE- 
indacaterol vs tiotropium) was performed. The primary endpoints of the clinical 
trials (Trough FEV1, Transition Dyspnea Index [TDI] and Saint Georges Respiratory 
Questionnaire [SGRQ]) were included in the cost-effectiveness analysis. Incremental 
cost effectiveness ratio (ICER) of indacaterol vs. tiotropium for different treatment 
success criteria (week 12 FEV1 > 0.12L increase, ≥ 1 improvement in TDI score, ≥ 4 
decrease in SGRQ score) were compared. Incremental cost effectiveness ratios were 
calculated over incremental differences versus placebo. Probabilistic sensitivity 
analysis was performed using the Bootstrap method. results: FEV1success rates 
at month 3 for indacaterol and ipratropium were 26.5% and 24.3%, respectively. At 
month 3, ICERs of indacaterol versus ipratropium were -1002TL for FEV1, -434TL for 
TDI and -878TL for SGRQ. At month 6, FEV1 success rates were 54.8 and 47.4%, TDI 
success rates were 58.7% and 54.4% and SGRQ success rates were 81.8% and 77.1%, 
respectively. ICERs of indacaterol versus ipratropium at month 6 were -616TL for 
FEV1, -1049TL for TDI and -1014TL for SGRQ conclusions: Based on this clinical 
trial-based analysis, indacaterol was cost effective treatment and cost reducing 
choice vs. tiotroprium in COPD treatment.
PRs4
A nEtWoRK MEtA-AnAlysis coMPARing thE EfficAcy And sAfEty 
of cEftoBiPRolE And sElEctEd coMPARAtoRs in thE tREAtMEnt of 
hosPitAl-AcquiREd PnEuMoniA
Pooley N.1, Chadda S.1, Madrigal A.M.2, Kuessner D.3, Posthumus J.4
1PHMR Associates, Newcastle upon Tyne, UK, 2PHMR Associates, London, UK, 3Basilea 
Pharmaceutica Ltd, Basel, Switzerland, 4Basilea Pharmaceutica International Ltd., Basel, 
Switzerland
oBjectives: Hospital-acquired pneumonia (HAP) is a severe respiratory tract infec-
tion which develops more than 48h after hospital admission. Ceftobiprole, the active 
moiety of its prodrug ceftobiprole medocaril, is a new cephalosporin with bactericidal 
activity against a broad spectrum of pathogens including resistant bacteria such as 
methicillin-resistant S. aureus (MRSA), penicillin-resistant pneumococci andP. aerugi-
nosa. Ceftobiprole was shown safe and effective for the treatment of HAP (excluding 
ventilator-associated pneumonia), when compared with linezolid plus ceftazidime 
in a large-scale phase-III clinical trial (NCT00210964). Methods: MEDLINE, EMBASE, 
Medline-In-Process and the Cochrane Library were searched for randomised con-
trolled trials that included ceftobiprole and/or comparators ceftazidime, meropenem, 
imipenem/cilastatin, piperacillin/tazobactam, ciprofloxacin, levofloxacin, moxifloxa-
cin and gentamicin as intervention in the treatment of HAP. The efficacy of ceftobi-
prole was compared to comparators using a random effects model implemented 
within a fully Bayesian framework. Primary outcome was clinical response after end 
of treatment in the clinically evaluable (CE) population. results: Eleven studies 
(2413 patients) with HAP were included in the analysis, 1618 patients were eligible 
for analysis of clinical response in the CE population. The comparative efficacies 
(odds ratio, 95% credible intervals) of ceftobiprole to each comparator were 0.92,0. 
092-8.8 (ceftazidime), 1.1, 0.054-19 (piperacillin/tazobactam), 1.9, 0.12-30 (meropenem), 
0.83, 0.019-32 (levofloxacin), 0.96, 0.047-16 (imipenem/cilastatin), and 0.87, 0.025-22 
(ciprofloxacin). No comparison was possible to gentamicin or moxifloxacin due to 
a lack of comparative studies against other comparators. No significant difference 
was seen between ceftobiprole and any comparator in clinical response or in any of 
the secondary outcomes, including mortality and adverse events conclusions: 
The results of this multi-treatment comparison support the comparable efficacy and 
safety of ceftobiprole to relevant comparators in the treatment of HAP. This analysis 
was limited by the small number of available studies, and by the fact that among the 
drugs compared, only ceftobiprole provides coverage of MRSA.
PRs5
coMPARAtivE EfficAcy of uMEclidiniuM BRoMidE vERsus othER long-
Acting AnticholinERgic MonothERAPiEs As tREAtMEnts foR coPd 
PAtiEnts
Ismaila A.1, Huisman E.2, Punekar Y.S.3
1GlaxoSmithKline, Research Triangle Park, NC, USA, 2Mapi - HEOR & Strategic Market Access, 
Houten, The Netherlands, 3GlaxoSmithKline, Uxbridge, UK
concerning the long term safety and effectiveness of the drugs when used on larger 
populations. Pharmaceutical companies face big challenges for the coming years 
especially in EU and there is an increase need for local regulatory knowledge. There’s 
still need to increase awareness for the importance of real world studies and the 
impact it has on the patient’s life.
PRM256
PuBlicAtion MAnuAl of BudgEt iMPAct AnAlysis (BiA) By thE 
dEPARtMEnt of sciEncE And tEchnology of thE MinistRy of hEAlth 
(dEcit)
Koury C.D.N.1, Elias F.T.S.2
1FIPE -Fundação de Ensino e Pesquisas Econômicas, Brasilia, Brazil, 2Ministry of Health of Brazil, 
Brasilia, Brazil
The epidemiological and economic methods applied to health technologies evalu-
ations had a significant development in the last two decades. The need to balance 
the incorporation of new technologies in health care and limited financial resources 
promoted the construction and application of instruments supporting the decision 
making of health technology. The requirement Budget Impact Analysis formally 
stated in Law 12.401/2011 establishing the incorporation process technologies in 
SUS. In this context, in 2010/2011, the National Agency of Sanitary Surveillance 
(ANVISA) and DECIT, in partnership Institute for Health Technology Assessment 
(IATS) for drawing up of this guideline. In the first stage of development were 
used international recommendations of Canada, Australia, the UK and Poland, 
the recommendations of the International Society for PharmacoEconomics and 
Outcomes Research (ISPOR) and the methods used in studies of budgetary impact 
that had already been published. Afterwards, drafted a preliminary version of the 
Guideline and a standard tool - Excel worksheets - to estimate the uptake of mon-
etary resources required for adoption of new technologies. Revisions were carried 
out by technicians DECIT and health agencies, and the proposal was submitted to 
the Working Group on Development of Methodology REBRATS, composed of experts 
and academic researchers from several Brazilian states. Were also carried out work-
shops for the application of spreadsheets. In 2012, the first edition of the Guidelines 
was published two thousand copies in Portuguese in order to provide best practice 
recommendations for studies of budget impact.
disEAsE - sPEcific studiEs
REsPiRAtoRy-RElAtEd disoRdERs – clinical outcomes studies
PRs1
PRosPEctivE study on cost-EffEctivEnEss of nuRsE intERviW 
intRoducing REtEsting With in vitRo diAgnostics (ivd) to PAREnts of 
childREn With susPEctEd food AllERgy in finlAnd
Hermansson L.L.1, Korhonen K.2, Silvan M.2, Rantanen S.2, Isoaho R.3, Savolainen J.3
1Thermo Fisher Scientific, Uppsala, Sweden, 2Härkätie Primary Care Center, Lieto, Finland, 
3University of Turku, Turku, Finland
oBjectives: Accordance to Finnish Allergy Program 2008-2018, to decrease food 
avoidance diets by 50%. Focus in algorithm with patient history +IVD in school 
children with suspected food allergy and reason for declining re-diagnosis. NICE 
clinical guideline (Food Allergy Diagnoses, 2011) suggested further work made 
on effect of diagnosing allergies in realistic population and cost effectiveness of 
retesting. Methods: Prospective trial with patients from Finnish primary care 
database (2885 school children). School kitchen had allergy restricted diets for 179 
children. In the pilot phase, 179 families were contacted by letter. Of the 24 who 
were included in pilot, 17 were not allergic (70%). In this study families were inter-
viewed by telephone. Of 156 families 107 agreed to participate in this study and 
47 children will be diagnosed by component resolved diagnostics (CRD) and 60 
with sIgE and CRD. results: Prevalence of food avoidance diets: 6,2%. Reasons for 
declining re-testing: 23 were not allergic, 9 were busy, 9 have own physician, 3 did 
not believe allergy tests, 8 scared of needles, 7 already tested, 4 tested often due to 
health problems, 2 in pilot study and 7 did not recognize a benefit. conclusions: 
Telephone consultation by nurse decreased special diets for 23 children (13%) and 39 
(22%) had non-medical reason to decline retesting. Nurse consultation to introduce 
retesting with IVD can be considered as cost effective approach in decreasing food 
avoidance diets in children.
PRs2
EffEctivEnEss of MontEluKAst on AsthMA contRol in infAnts:  
A clAiMs dAtA study
Belhassen M.1, Ginoux M.1, Laigle V.2, chanut-Vogel C.2, Lamezec L.2, de Blic J.3, Fauroux B.3, 
de Pouvourville G.4, Laforest L.1, Van Ganse E.1
1University of Lyon, Lyon, France, 2Laboratoires MSD France, Courbevoie, France, 3Pediatric 
Medicine Necker University, Paris, France, 4ESSEC Business School, Cergy, France
oBjectives: Montelukast 4mg (MTL-4) is an add-on therapy for asthmatic infants. 
Given the quality and exhaustivity of the data, French claims data (SNIIR-AM) is a 
relevant tool to investigate MTL-4 effectiveness in infants. The objective was to com-
pare the effectiveness of MTL-4, associated or not with ICS, vs. ICS without MTL-4, on 
health outcomes of infants with mild to moderate uncontrolled asthma. Methods: 
Infants (6-24 months) receiving ≥ 2 consecutive dispensing of respiratory drugs from 
2010 to 2011, and presenting an initial exacerbation within 6 months of the first 
dispensing were preselected. Asthma-related outcomes included hospitalizations, 
dispensing of oral corticosteroids, addition of short-acting beta agonists to exist-
ing respiratory therapy, switch to a higher ICS dosage, or nebulized CS. The studied 
groups were infants receiving MTL-4 +/- ICS (MTL-4 group) and infants receiving 
ICS without MTL-4 (ICS group). The two groups were matched, e. g. on initial therapy 
before initial exacerbation and past asthma related hospitalization. The two groups 
were compared, as to the occurrence of a new exacerbation and the total num-
